ACS Chemical Neuroscience
June 17, 2026
Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.
Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...
Pharmaceutical Sciences
April 30, 2026
Elmira Zolali, Lance R Mcmahon, Samuel Obeng
Please don't use dangerous characters * Last Name Please don't use dangerous characters * Email Address Please enter a email address * Comments Please don't use dangerous characters * Security code The entered code is invalid. Generate New Image Type the code from the image Abstract View: 388 Your browser does not support the canvas element. yearsJanFebMarAprMayJunJulAugSepOctNovDec...
Pharmacological reports : PR
April 1, 2026
Elmira Zolali, Mallory Burns, Sebastiano Intagliata et al.
BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...
Psychopharmacology
February 7, 2025
Sabrina Zequeira, Emely A. Gazarov, Alara A. Güvenli et al.
With increasing legalization of recreational and medical cannabis, use of this drug is growing rapidly among older adults. As cannabis can impair cognition in young adults, it is critically important to understand how its consumption interacts with the cognitive profile of aged subjects, who are already at increased risk of decline. The current study was designed to determine how cannabis...